Director Mulligan Seamus purchases 101,621 shares for $9,993,081.71 at Jazz Pharmaceuticals in 4 separate transactions May 9–12.
Mulligan executed 4 separate purchases totaling 101,621 shares for $9,993,081.71, with a blended average price of $98.34, establishing a zero-to-substantial position in Jazz Pharmaceuticals. The purchases occurred over a three-day window (May 9–12, 2025) at prices clustered around $98–$103, slightly below the current price of $102.91 but well below the 52-week high of $144.17. The stock is down 28.6% from its 52-week peak and down 24.0% over the past 90 days, though it has recovered 2.4% in the last 30 days. The company is currently unprofitable (net income of -$92.5M in the latest quarter) despite steady revenue growth of 6.1% year-over-year, and trades at a P/E of 13.16 on a $6.3B market cap. The scale of this buy—a de novo $10.0M equity stake by a director—warrants attention to whether this represents confidence in recovery or an opportunistic entry at a depressed price point.